X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (21) 21
humans (19) 19
index medicus (17) 17
female (16) 16
aged (14) 14
chemotherapy (13) 13
middle aged (13) 13
adult (12) 12
antineoplastic combined chemotherapy protocols - therapeutic use (10) 10
antineoplastic combined chemotherapy protocols - adverse effects (9) 9
breast cancer (9) 9
breast neoplasms - drug therapy (9) 9
aged, 80 and over (8) 8
disease-free survival (8) 8
bevacizumab (7) 7
breast neoplasms - pathology (6) 6
care and treatment (6) 6
paclitaxel - administration & dosage (6) 6
survival (6) 6
taxoids - administration & dosage (6) 6
therapy (6) 6
treatment outcome (6) 6
adjuvant chemotherapy (5) 5
cancer (5) 5
clinical trials (5) 5
docetaxel (5) 5
france (5) 5
metastatic breast cancer (5) 5
ovarian cancer (5) 5
quality of life (5) 5
young adult (5) 5
antineoplastic combined chemotherapy protocols - administration & dosage (4) 4
cisplatin (4) 4
drug administration schedule (4) 4
drug therapy (4) 4
hematology, oncology and palliative medicine (4) 4
medicine & public health (4) 4
metastasis (4) 4
ovarian neoplasms - drug therapy (4) 4
pegylated liposomal doxorubicin (4) 4
survival rate (4) 4
taxoids - adverse effects (4) 4
adolescent (3) 3
analysis (3) 3
antibodies, monoclonal, humanized - administration & dosage (3) 3
antibodies, monoclonal, humanized - adverse effects (3) 3
cabazitaxel (3) 3
cancer therapies (3) 3
carboplatin (3) 3
carboplatin - administration & dosage (3) 3
carcinoma (3) 3
chemotherapy, adjuvant (3) 3
doxorubicin - analogs & derivatives (3) 3
enzalutamide (3) 3
fluorouracil - administration & dosage (3) 3
male (3) 3
multicenter (3) 3
neoplasm staging (3) 3
paclitaxel (3) 3
paclitaxel - adverse effects (3) 3
patient outcomes (3) 3
prognosis (3) 3
progression (3) 3
proportional hazards models (3) 3
prospective studies (3) 3
survival analysis (3) 3
trastuzumab (3) 3
triple negative (3) 3
1st-line treatment (2) 2
abiraterone (2) 2
adenocarcinoma - drug therapy (2) 2
adjuvant treatment (2) 2
antibodies, monoclonal, humanized (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic agents - therapeutic use (2) 2
bevacizumab - administration & dosage (2) 2
biomarkers, tumor - analysis (2) 2
breast neoplasms - chemistry (2) 2
breast neoplasms - genetics (2) 2
breast neoplasms - mortality (2) 2
breast neoplasms - surgery (2) 2
capecitabine (2) 2
castration-resistant prostate cancer (2) 2
clinical-trials (2) 2
cyclophosphamide (2) 2
cyclophosphamide - administration & dosage (2) 2
deoxycytidine - administration & dosage (2) 2
deoxycytidine - analogs & derivatives (2) 2
disease progression (2) 2
dosage and administration (2) 2
dose-response relationship, drug (2) 2
double-blind method (2) 2
doxorubicin - administration & dosage (2) 2
doxorubicin - adverse effects (2) 2
early breast cancer (2) 2
efficacy (2) 2
epirubicin - administration & dosage (2) 2
epithelial ovarian (2) 2
fluorouracil - adverse effects (2) 2
follow-up studies (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 12/2009, Volume 27, Issue 36, pp. 6129 - 6134
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2019, Volume 37, Issue 34, pp. 3183 - 3191
PURPOSE This study estimated time without symptoms or toxicity (TWiST) with niraparib compared with routine surveillance (RS) in the maintenance treatment of... 
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 09/2019, Volume 25, Issue 17, pp. 5342 - 5350
Purpose: Regarding cancer antigen 125 (CA-125) longitudinal kinetics during chemotherapy, the actual predictive value of the Gynecologic Cancer... 
PHASE-III TRIAL | 1ST-LINE TREATMENT | SURROGATE | ONCOLOGY | BEVACIZUMAB | CARBOPLATIN PLUS PACLITAXEL | ANTIGEN 125 | EPITHELIAL OVARIAN | CHEMOTHERAPY | PREDICTION | PARAMETER
Journal Article
European Journal of Cancer, ISSN 0959-8049, 08/2019, Volume 117, pp. 99 - 106
Platinum-resistant ovarian cancer (PROC) is associated with a variable prognosis and unpredictable survival times. We have developed and validated a prognostic... 
Platinum-resistant ovarian cancer | Overall survival | Prognostic nomogram | TRIAL | RELAPSE | ONCOLOGY | PREDICT | PROGRESSION | Care and treatment | Chemotherapy | Patient outcomes | Analysis | Ovarian cancer | Cancer
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 01/2019, Volume 152, Issue 1, pp. 68 - 75
Carboplatin and pegylated liposomal doxorubicin combination is a standard regimen in platinum-sensitive recurrent ovarian cancer patients. The pegylated... 
Journal Article
Cancer, ISSN 0008-543X, 10/2016, Volume 122, Issue 20, pp. 3119 - 3126
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.